Dechert Advises Crossject on Capital Increase and Issuance of Warrants to Long-Standing Investors and New U.S. Investors
December 17, 2024
December 17, 2024
PHILADELPHIA, Pennsylvania, Dec. 17 -- Dechert, a law firm, issued the following news:
Dechert advised Crossject, a pharmaceutical company specializing in the development of drugs using its needle-free auto-injector ZENEO(R), in connection with a capital increase reserved for a category of investors and the issuance of warrants for a total amount of Euros7.2 million.
Simultaneously, Crossject reached an agreement with Heights Capital Management to amend the terms and co . . .
Dechert advised Crossject, a pharmaceutical company specializing in the development of drugs using its needle-free auto-injector ZENEO(R), in connection with a capital increase reserved for a category of investors and the issuance of warrants for a total amount of Euros7.2 million.
Simultaneously, Crossject reached an agreement with Heights Capital Management to amend the terms and co . . .